Antibody-based targeting of angiogenesis.
The selective targeting of neovasculature opens new avenues for the diagnosis and therapy of angiogenesis-related diseases such as cancer, blinding ocular disorders, and rheumatoid arthritis. Here we review recent advances in the identification of markers of angiogenesis as well as in the isolation and use of antibodies (and their derivatives) for the in vivo targeting of both tumoral and nontumoral neovasculature.
Halin
C
C
Institute of Pharmaceutical Sciences, Department of Applied Biosciences, Swiss Federal Institute of Technology, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
Zardi
L
L
Neri
D
D
D000818:Animals; D001766:Blindness / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D005123:Eye / Q000098:blood supply; D006801:Humans; D007158:Immunologic Techniques; D009369:Neoplasms / Q000098:blood supply* / Q000175:diagnosis / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000150:complications* / Q000209:etiology*